Ingalls & Snyder LLC Has $3.50 Million Holdings in Novo Nordisk A/S $NVO

Ingalls & Snyder LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 2.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,681 shares of the company’s stock after selling 1,130 shares during the quarter. Ingalls & Snyder LLC’s holdings in Novo Nordisk A/S were worth $3,498,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of NVO. Copeland Capital Management LLC lifted its stake in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $27,000. Stone House Investment Management LLC bought a new stake in shares of Novo Nordisk A/S in the first quarter worth $30,000. Disciplina Capital Management LLC boosted its holdings in Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 297 shares during the last quarter. Finally, Dagco Inc. bought a new position in Novo Nordisk A/S in the first quarter valued at $35,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $53.02 on Friday. The company has a market cap of $236.74 billion, a P/E ratio of 14.57, a P/E/G ratio of 2.41 and a beta of 0.68. The firm’s fifty day moving average price is $56.56 and its two-hundred day moving average price is $62.40. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $114.19. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 22.53%.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. HSBC set a $70.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, October 1st. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. UBS Group cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. TD Cowen lowered their price target on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 19th. Finally, BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $76.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.